Sign In
  • A-
  • A
  • A+
  • ع
  • A-
  • A
  • A+
  • ع
Dr.Mutasem (Mark) RAWAS-QALAJI Academic RankAssociate Professor

Specialization:

  • Pharmaceutical Sciences.

Research Interests:

  • Nanotechnology, Formulation & Drug Delivery, Translational Research, Non-Invasive Drug Delivery.

Contact

Bachelor of Pharmacy (B.Pharm.) Doctor of Philosophy (Ph.D.)
1)Nova Southeastern University, Fort Lauderdale, FL, USA 2)EnWave Corp., Vancouver, BC, Canada 3)Quadra Logic Technologies (QLT) Inc., Vancouver, BC, Canada 4)University of Manitoba, Winnipeg, MB, Canada 5)F. Hoffmann-La Roche Ltd, Riyadh, Saudi Arabia
Invited External Examiner (Ph.D. Dissertation), College of Graduate and Postdoctoral Studies, University of Saskatchewan, Saskatoon, Canada, June 25, 2018 Invited External Reviewer, Technology Commercialization Fund program, University of Connecticut, December 2017 Invited Primary Grant Reviewer, Qatar University, October 2017 Invited Primary Grant Reviewer, Long Lasting Medications Panel, NASA-Translational Research Institute (TRI), 2017 and 2019 Invited External Committee Member (Ph.D. Dissertation), Center of Research, Anna University, India, Aug 2017 Represented NSU and College of Pharmacy at the International Exhibition and Conference on Higher Education, Riyadh, Saudi Arabia, April 12-25, 2017. Represented NSU-TRED at BioFlorida Annual Conference, Jacksonville, FL, Dec 11-13, 2016. Represented NSU-TRED at FierceBiotech Drug Development Forum, Boston, MA, Sep 18-21, 2016. Represented NSU- and College of Pharmacy at eMerg Americas Tech Conference, Miami, FL, May 2-5, 2015 Invited Grant Reviewer for President’s Faculty Research and Development Grant (PFRDG), NSU (2014) Abstracts Reviewer for Health Professions Division (HPD) Research Day, NSU (2012-2013) Invited External Member of Faculty Tenure/Promotion Committee for Texas A&M College of Pharmacy, July 2013 Invited External Grant Reviewer for California Northstate University College of Pharmacy Seed Grant, 2012-2013 Bioequivalence Focus Group: Active Member American Association of Pharmaceutical Scientists (AAPS), 2012-2018. Role: promote understanding of equivalence of different dosage forms, develop programs and publications for AAPS annual meeting and National Biotechnology conferences In Vitro Release and Dissolution Testing (IVRDT) Focus Group: Active Member American Association of Pharmaceutical Scientists (AAPS), 2013-2018. Role: promote understanding of IVRDT, develop programs and publications for AAPS annual meeting and National Biotechnology conferences Excipients Focus Group: Active Member American Association of Pharmaceutical Scientists (AAPS), 2012-2018. Role: promote understanding of Excipients utilization, develop programs and publications for AAPS annual meeting and National Biotechnology conference Invited Mentor at the Career Mentoring Breakfast Canadian Society for Pharmaceutical Sciences (CSPS) Annual Symposium, Richmond, BC, Canada, June 2-5, 2010. Invited Curriculum Reviewer for the Department of Pharmaceutics and Pharmaceutical Technology, Ebla Private University, Aleppo, Syria, June 2010. Reviewer in peer-reviewed journals for manuscripts submitted for publication (Journal of Pharmaceutical Scientist, International Journal of Pharmaceutics, Journal of Biopharmaceutics and Drug Disposition, Journal of Materials Research Society Bulletin, Journal of AAPSPharmaSciTech, Journal of Biomaterials Science: Polymer Edition, British Journal of Pharmaceutical Research, etc.) Reviewer of submitted conferences abstracts for poster presentation and publication in peer-reviewed journals or conference proceedings (American Association of Pharmaceutical Scientists (AAPS) Annual Conference, AAPS National Biotechnology Conference, and Materials Research Society (MRS) Annual Conference, 2010-present).
Quality Enhancement Plan Committee (Member), NSU (2014-2019) *College of Pharmacy Level* Visionary Education Team for Strategic Planning (Member), College of Pharmacy, NSU (2017-present) Pharm. D. Curriculum – Basic Knowledge Group (Chair), College of Pharmacy, NSU (2016-present) Visionary Education Modular Development Taskforce (Member), College of Pharmacy, NSU (2015-2016) Ph.D. Admission Committee (Member), College of Pharmacy, NSU (2014-present) Research Committee (Member), College of Pharmacy, NSU (2014-2015) Ph.D. Dissertation Committee (Chair), College of Pharmacy, NSU (2013-present) Ph.D. Dissertation Committee (Member), College of Pharmacy, NSU (2013-2017) Inter-professional Education (IPE) Committee (Member), College of Pharmacy, NSU (2015-2016) Pharm. D. Curriculum Committee (Member), College of Pharmacy, NSU (2012-present) AACP Accreditation Self-Study Committee-Curriculum standards (Team Leader), College of Pharmacy, NSU (2013-2014) Pharm. D. Curriculum Outcomes Sub-Committee (Member), College of Pharmacy, NSU (2012-2013) Ph.D. Curriculum Committee (Member), College of Pharmacy, NSU (2010-2013) Admissions Committee (Member), College of Pharmacy, NSU (2008-2012) Interviewing students applying for admission into the College of Pharmacy, NSU (2008-present) Faculty Student’s Advisor, College of Pharmacy, NSU (2009-present) Graduate Students Representative, Faculty of Pharmacy, University of Manitoba (2005-2006) Graduates Students Awards Committee (Member), Faculty of Pharmacy, University of Manitoba (2005-2006) Department of Pharmaceutical Sciences Level: Curriculum and Assessment Committee (Chair), Department of Pharmaceutical Sciences, College of Pharmacy, NSU (2015-present) Faculty Recruitment Committee (Chair), Department of Pharmaceutical Sciences, College of Pharmacy, NSU (2010-2014) Ph.D. Curriculum Committee (Chair), Department of Pharmaceutical Sciences, College of Pharmacy, NSU (2012-2013) Department Secretary Recruitment Committee (Member), Department of Pharmaceutical Sciences, College of Pharmacy, NSU (for Krista Marshall in 2011 and Christie Priemer in 2012) Pharmaceutics Sub-curriculum Committee (Member), Department of Pharmaceutical Sciences, College of Pharmacy, NSU (2009-2010) Faculty Recruitment Committee (Member), Department of Pharmaceutical Sciences, College of Pharmacy, NSU (2008-2010) Scholarship and Faculty Development Committee (Member), Department of Pharmaceutical Sciences, College of Pharmacy, NSU (2008-2009) Curriculum and Assessment Committee (Member), Department of Pharmaceutical Sciences, College of Pharmacy, NSU (2008-2009).
Epinephrine Sublingual Tablets for Pediatrics A fast-disintegrating sublingual tablet (FDST) of epinephrine (Epi) for the treatment of anaphylaxis in adults has been successfully developed and extensively evaluated in vitro and in vivo for the non-invasive treatment of anaphylaxis. In this formulation, Epi microcrystals/nanocrystals were developed and enhanced Epi permeation and absorption from the sublingual route by 2-fold using our developed taste-masked FDST platform. This allowed for the reduction of the required sublingual dose by 50% compared to the 1st generation formulation. Recently, we were able to optimize the physical characteristics of the Epi FDST by modifying the excipients’ grades used for pediatric application. Also, modifying the sublingual microenvironment’s pH using pH-modifying excipients resulted in significant enhancement in Epi sublingual permeability. The use of penetration enhancers in the tablet formulation was evaluated as well. These findings should allow for further reduction of the required Epi sublingual dose. In addition, it would facilitate the development of smaller Epi FDST dosage form or even alternative dosage forms for pediatric use. These results will be presented during the AAPS annual meeting in Washington, DC (Nov 4-7, 2018). My current goals are to develop various pediatric sublingual formulations using the previously obtained results and evaluate them in vivo to determine the sublingual Epi doses bioequivalent to the pediatric Epi intramuscular doses using auto-injectors. Atropine Sublingual Tablets Atropine is a well-known antimuscarinic (anticholinergic) drug that is frequently used in several indications including life threatening and emergency conditions to restore breathing, cardiac function and blood pressure. For the emergency treatment of organophosphates poising due to exposure to nerve agents or insecticides, atropine intramuscular (IM) injection is the drug of choice as a life-saving antidote medication. Away from healthcare facility, atropine auto-injectors (AtroPen®) are provided in few countries, for self-injection, to civilians or veterans at risk of organophosphates poising. In this project, novel rapidly disintegrating sublingual tablets (RDSTs) of atropine are proposed for the first time as an alternative, user-friendly, non-invasive, cost-effective dosage form for the emergency treatment of organophosphates toxicity away from health care facility. Recently, we were able develop and characterize fast-disintegrating sublingual atropine tablet at wide range of doses. The excipients’ grades were modified to optimize the physical characteristics of atropine FDST. Also, modifying the sublingual microenvironment’s pH using pH-modifying excipients resulted in significant enhancement in atropine sublingual permeability through excised sublingual membranes. My current goals are to perform a proof-of-concept studies for the feasibility of sublingual atropine delivery and determine the bioequivalent dose compared to atropine IM injections using fast-disintegrating sublingual atropine tablet in a validated animal.
1.Bafail R, Rawas-Qalaji MM, Rawas-Qalaji M, Aodah AH,. Effect of the Filler Grade on the Characteristics and the Sublingual Permeability of Atropine Sulfate Fast Disintegrating Sublingual Tablets. Drug Dev Ind Pharm. 2019 45:10, 1617-1623. PMID: 31353966. DOI: 10.1080/03639045.2019.1648499. (Impact factor: 2.3) 2.Aodah AH, Rawas-Qalaji MM, Bafail R, Rawas-Qalaji MM. Effect of Fast-Disintegrating Tablets’ Characteristics on the Sublingual Permeability of Atropine Sulfate for the Potential Treatment of Organophosphates Toxicity. AAPS PharmSciTech, Jun 21;20(6):229. PMID: 31227930. DOI: 10.1208/s12249-019-1420-1 (Impact factor: 2.6) 3.Yamada C, Beron-Pelusso C, Algazzaz N, Heidari A, Luz D, Rawas-Qalaji M, Toderas I, Mascarenhas AK, Kawai T, Movila A. Age-dependent effect between MARCO and TLR4 on PMMA particle phagocytosis by macrophages. J Cell Mol Med. 2019 Aug;23(8):5827-5831. (Impact factor: 4.7) PMID: 31225947. DOI: 10.1111/jcmm.14494. 4.Rachid OM, Simons KJ, Rawas-Qalaji MM. In Vivo Evaluation of Taste-Masked Fast-Disintegrating Sublingual Tablets of Epinephrine Microcrystals. AAPS PharmSciTech 2018; Nov;19(8):3886-3894. (Impact factor: 2.6) PMID: 30324360. DOI: 10.1208/s12249-018-1171-4. 5.Rachid OM, Rawas-Qalaji MM, Simons KJ. Epinephrine in anaphylaxis: Preclinical study of pharmacokinetics after sublingual administration of taste-masked tablets for potential pediatric use. Pharmaceutics 2018;10(1):24. PMID: 29439456. DOI:10.3390/pharmaceutics10010024 (Impact factor: 3.7) 6.Aodah AH, Bafail R, Rawas-Qalaji MM. Formulation and Evaluation of Fast-Disintegrating Sublingual Tablets of Atropine Sulfate: the Effect of Tablet Dimensions and Drug Load on Tablet Characteristics. AAPS PharmSciTech 2017;18(5):1624-1633 (Times Cited: 1, Impact factor: 2.6) PMID: 27650282. DOI: 10.1208/s12249-016-0631-y 7.Rachid OM, Simons ER, Rawas-Qalaji MM, Lewis S, Simons KJ. Epinephrine doses delivered from auto-injectors stored at excessively high temperatures. Drug Dev Ind Pharm 2016;42(1):131-5. (Impact factor: 2.3) PMID: 25997362. DOI: 10.3109/03639045.2015.1035283 8.Rawas-Qalaji MM, Werdy SH, Rachid OM, Simons KJ, Simons ER. Sublingual Diffusion of Epinephrine Microparticles from Rapidly Disintegrating Tablets for the Potential First-Aid Treatment of Anaphylaxis: In Vitro and Ex Vivo Study. AAPS PhamSciTech 2015; 16(5): 1203-12. (Impact factor: 2.6) PMID: 25732373. DOI: 10.1208/s12249-015-0306-0. 9.Rachid OM, Simons ER, Wein MB, Rawas-Qalaji MM, Simons KJ. Epinephrine Doses Contained in Outdated Epinephrine Auto-Injectors Collected in a Florida Allergy Practice. Ann Allergy Asthma Immunol. 2015; 114(4):354-356 (Impact factor: 3.7) PMID: 25707326. DOI: 10.1016/j.anai.2015.01.015 10.Rachid OM, Simons ER, Rawas-Qalaji MM, Lewis S, Simons KJ. Epinephrine Autoinjectors: Does Freezing or Refrigeration Affect Epinephrine Dose Delivery and Enantiomeric Purity? J Allergy Clin Immunol Pract 2015; 3(2):294-6. (Impact factor: 5.3) PMID: 25609348. DOI: 10.1016/j.jaip.2014.11.015. 11.Rawas-Qalaji MM, Rachid OM, Mendez BA, Losada A, Simons ER, Simons KJ. Adrenaline (Epinephrine) Microcrystal Sublingual Tablet Formulation: Enhanced Absorption in a Preclinical Model. J Pharm Pharmacol 2015; 67(1):20-5 (Impact factor: 2.4) PMID: 25256073. DOI: 10.1111/jphp.12312. 12.Alayoubi A, Abu-Fayyad A, Rawas-Qalaji MM, Sylvester P, Nazzal S. Effect of Lipid Viscosity and High-Pressure Homogenization on The Physical Stability of “Vitamin E” Enriched Emulsion. Pharm. Dev. Technol. 2015; 20(5):555-61. (Impact factor: 1.9) PMID:24621375. DOI: 10.3109/10837450.2014.898655. 13.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Long-Term Stability of Epinephrine Sublingual Tablets for the Potential First-Aid Treatment of Anaphylaxis. Ann Allergy Asthma Immunol. 2013:111:567-79. (Impact factor: 3.7) PMID: 24267371. DOI: 10.1016/j.anai.2013.09.005. 14.Rachid OM, Rawas-Qalaji MM, Simons FER, Simons KJ. Epinephrine (Adrenaline) Absorption from New-Generation, Taste-Masked Sublingual Tablets: A Preclinical Study. J Allergy Clin Immunol. 2013;131(1):236-8. (Impact factor: 13) PMID:23177259. DOI: 10.1016/j.jaci.2012.10.016. 15.Rachid OM, Rawas-Qalaji MM, Simons FER, Simons KJ. Rapidly-disintegrating sublingual tablets of epinephrine: role of non-medicinal ingredients in formulation development. Eur J Pharm Biopharm. 2012 Jun 7;82(3):598-604. (Impact factor: 4.2) PMID: 22683694. DOI: 10.1016/j.ejpb.2012.05.020. 16.Rawas-Qalaji MM&, Williams C*. Advances in Ocular Drug Delivery. Curr Eye Res. 2012; 37(5):345-356. (Impact factor: 2.2) PMID: 22510004. DOI: 10.3109/02713683.2011.652286. 17.Rachid OM, Rawas-Qalaji MM, Simons FER, Simons KJ. Dissolution Testing of Sublingual Tablets: A Novel In Vitro Method. AAPS PhamSciTech. 2011 Jun;12(2):544-52. (Impact factor: 2.6) PMID: 21523516. DOI: 10.1208/s12249-011-9615-0. 18.Rachid OM, Simons FER, Rawas-Qalaji MM, Simons KJ. An Electronic Tongue: Evaluation of the Masking Efficacy of Sweetening and/or Flavoring Agents on the Bitter Taste of Epinephrine. AAPS PhamSciTech. 2010 Jun;11(2):550-7. (Impact factor: 2.6) PMID: 20352537. DOI: 10.1208/s12249-010-9402-3. 19.Rawas-Qalaji MM, Simons ER, Simons KJ. Long-Term Stability of Epinephrine Dispensed in Unsealed Syringes for the First-Aid Treatment of Anaphylaxis. Ann Allergy Asthma Immunol. 2009;102(6):500-503. (Impact factor: 3.7) PMID: 19558009. DOI: 10.1016/S1081-1206(10)60124-X 20.Rawas-Qalaji MM, Simons ER, Simons KJ. Fast-Disintegrating Sublingual Tablets: Effect of Tablet Dimensions on Tablet Characteristics. Drug Dev Ind Pharm. 2007;33(5):523-530. (Impact factor: 2.3) PMID: 17520443. DOI: 10.1080/03639040600897150. 21.Rawas-Qalaji MM, Simons ER, Simons KJ. Epinephrine for the Treatment of Anaphylaxis: Do all 40 mg Sublingual Epinephrine Tablet Formulations with Similar In Vitro Characteristics have the Same Bioavailability?. Biopharm Drug Dispos. 2006;27(9):427-435. (Impact factor: 2.1) PMID: 17009337. DOI: 10.1002/bdd.519. 22.Rawas-Qalaji MM, Simons ER, Simons KJ. Fast-Disintegrating Sublingual Tablets: Effect of Epinephrine Load on Tablet characteristics. AAPS PharmSciTech. 2006;7(2): E41 (Article Number 41). (Impact factor: 2.6) PMID: 16796358. DOI: 10.1208/pt070241. 23.Rawas-Qalaji MM, Simons ER, Simons KJ. Sublingual Epinephrine Tablets Versus Intramuscular Injection of Epinephrine: Dose Equivalence for Potential Treatment of Anaphylaxis. J Allergy Clin Immunol. 2006; 117(2):398-403. (Impact factor: 13) PMID: 16461140. DOI: 10.1016/j.jaci.2005.12.1310. 24.Ousama Rachid, Mutasem Rawas-Qalaji and Keith J. Simons. Epinephrine in Anaphylaxis: Preclinical Study of Pharmacokinetics after Sublingual Administration of Taste-Masked Tablets for Potential Pediatric Use. In: Neal M. Davies and Kishor M. Wasan (Eds.). Pharmacokinetics and Drug Metabolism in Canada: The Current Landscape. Basel, Switzerland: MDPI Books; (March) 2018. ISBN 978-3-03842-797-1 (Pbk); ISBN 978-3-03842-798-8 (PDF). DOI: 10.3390/books978-3-03842-798-8
Ph.D. Program (Thesis): 1-2011-2017: Formulation and Evaluation of Rapidly Disintegrating Sublingual Atropine Tablets for the Potential Treatment of Acute Organophosphates Toxicity 2-2011-2016: Quantitative Assessment of Dipivefrin Hydrolysis Using HPLC-PDA in Media Simulating In vitro and In vivo Matrices for Potential Sublingual Administration for First-Aid Treatment of Anaphylaxis 3-2013-2019: Enhancing the Sublingual Permeability of Atropine Sulfate: Effect of pH and Penetration Enhancers 4-2017-present: In Vivo Evaluation of Fast Disintegrating Sublingual Atropine Tablets for Organophosphates Toxicity Treatment Dental Resident Research Project: 5-2011-2012: In Vitro Quantification of Xylitol Released from Commercial Tooth wipes
Group 12 (NSU18-05): Optimization of Epinephrine Sublingual Permeability 1.Rawas-Qalaji MM. Sublingual Epinephrine Compositions Including pH-Modifying Excipients and Penetration Enhancers. US Provisional Patent Appl # 62/748,117. Filed October 19, 2018. Assignee: Nova Southeastern University. 2.Rawas-Qalaji MM. Sublingual Epinephrine Compositions Including pH-Modifying Excipients and Penetration Enhancers. International Patent Pub (WIPO) # PCT/US19/. Filed October 19, 2018. Assignee: Nova Southeastern University. Group 11 (NSU 16-01): Formulation Optimization and Diffusion Evaluation of Rapidly Disintegrating Sublingual Atropine Sulfate Tablets (2nd Generation) 3.Rawas-Qalaji MM, Bafail R. Atropine Sulfate Rapidly-Disintegrating Sublingual Tablets, Methods for Manufacture Thereof, and Methods for Use Thereof for Treatment of Acute Organophosphate Toxicity. US Provisional Patent Appl # 62/383,115. Filed September 2, 2016. Assignee: Nova Southeastern University. 4.Rawas-Qalaji MM, Bafail R. Atropine Sulfate Rapidly-Disintegrating Sublingual Tablets, Methods for Manufacture Thereof, and Methods for Use Thereof for Treatment of Acute Organophosphate Toxicity. International Patent Pub (WIPO) # PCT/US17/50030 (Appl No PCT/US2017/050030). Filed September 5, 2017 and published March 8, 2018. Assignee: Nova Southeastern University. 5.Rawas-Qalaji MM, Bafail R. Atropine Sulfate Rapidly-Disintegrating Sublingual Tablets of Improved Formulation, Methods for Manufacture Thereof, and Methods for Treatment of Acute Organophosphate Toxicity. US Patent Pub (USPTO) # US2019/ 0247296. Filed September 5, 2017 and published August 5, 2019. Assignee: Nova Southeastern University. Group 10 (NSU 15-12): Formulation and Evaluation of Cobalamin Composition for Improving Cognitive Function in Humans 6.Rawas-Qalaji MM, Deth R. Cobalamin Composition and Use Thereof for Improving Cognitive Function in Humans. US Provisional Patent Appl # 62/301,876. Filed March 1, 2016. Assignee: Nova Southeastern University. 7.Rawas-Qalaji MM, Deth R. Cobalamin Composition and Use Thereof for Improving Cognitive Function in Humans. International Patent Pub (WIPO) # WO/2017/151723 (Appl No PCT/US2017/020125), Filed March 1, 2017 and published September 8, 2017. Assignee: Nova Southeastern University. 8.Rawas-Qalaji MM, Deth R. Cobalamin Composition and Use Thereof for Improving Cognitive Function in Humans. US Patent Pub (USPTO) # US2019/0030061. Filed August 30, 2018 and published January 31, 2019. Assignee: Nova Southeastern University Group 9 (NSU 14-09): (a) Formulation and Characterization of 1st Generation Rapidly Disintegrating Sublingual Atropine Sulfate Tablets (b) Diffusion Studies of Rapidly Disintegrating Sublingual Atropine Sulfate Tablets (1st Generation) 9.Rawas-Qalaji MM, Aodah AH. Atropine Sulfate Rapidly-Disintegrating Sublingual Tablets, Methods for Manufacture Thereof, and Methods for Use Thereof for Treatment of Acute Organophosphate Toxicity. US Provisional Patent Appl (UPSTO) # 62/058722. Filed October 2, 2014. Assignee: Nova Southeastern University. 10.Rawas-Qalaji MM, Aodah AH. Atropine Sulfate Rapidly-Disintegrating Sublingual Tablets, Methods for Manufacture Thereof, and Methods for Use Thereof for Treatment of Acute Organophosphate Toxicity. International Patent Pub (WIPO) # WO/2016/054504 (Appl No PCT/US2015/053713). Filed October 2, 2015 and published July 4, 2016. Assignee: Nova Southeastern University 11.Rawas-Qalaji MM, Aodah AH. Atropine Sulfate Rapidly-Disintegrating Sublingual Tablets, Methods for Manufacture Thereof, and Methods for Use Thereof for Treatment of Acute Organophosphate Toxicity. US Patent Pub (USPTO) # US2017/0246158 Appl No 15516444). Filed April 3, 2017 published Aug 31, 2017. Assignee: Nova Southeastern University 12.Rawas-Qalaji MM, Aodah AH. Atropine Sulfate Rapidly-Disintegrating Sublingual Tablets, Methods for Manufacture Thereof, and Methods for Use Thereof for Treatment of Acute Organophosphate Toxicity. European Patent Pub (EPO) # EP3200793 (Appl No 15847897). Filed April 12, 2017 and published August 9, 2017. Assignee: Nova Southeastern University (Granted, will be issued in UK, France, Germany, Italy, Spain) 13.Rawas-Qalaji MM, Aodah AH. Atropine Sulfate Rapidly-Disintegrating Sublingual Tablets, Methods for Manufacture Thereof, and Methods for Use Thereof for Treatment of Acute Organophosphate Toxicity. Canadian Patent Pub (CIPO) # CA2963525. Filed April 12, 2017 and published August 9, 2017. Assignee: Nova Southeastern University Group 8 (NSU13-03-04): (a) In vitro/Ex vivo Diffusion Studies of Rapidly Disintegrating Sublingual Epinephrine Nanocrystals Tablets (3rd Generation) and (b) Bioavailability and Absorption Studies of Rapidly Disintegrating Sublingual Epinephrine Nanocrystals Tablets (3rd Generation) 14.Rawas-Qalaji, MM, Rachid, OM, Simons, KJ, Simons, ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Provisional Patent Appl (UPSTO) # 61/804,892. Filed March 25, 2013. Assignee: Nova Southeastern University. 15.Rawas-Qalaji, MM, Rachid, OM, Simons, KJ, Simons, ER. Epinephrine Fine particles and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. International Patent Pub (WIPO) # WO/2014/153559 (Appl No PCT/US14/31579). Filed March 24, 2014 and published September 25, 2014. Assignee: Nova Southeastern University. 16.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Fine particles and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Patent Pub (USPTO) # US2016/0045457 (Appl No 14/778,887). Filed September 21, 2015 and published February 18, 2016. Assignee: Nova Southeastern University 17.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Fine particles and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. European Patent Pub (EPO) # EP2976072 (Appl No 14768584). Filed March 24, 2014 and published January 27, 2016. Assignee: Nova Southeastern University 18.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER Epinephrine Fine particles and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. Canadian Patent Pub (CIPO) # CA2907770 (Appl No 2,907,770). Filed March 24, 2014 and published January 27, 2016. Assignee: Nova Southeastern University 19.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER Epinephrine Fine particles and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Patent Pub (USPTO) # US2017/0020827 (Appl No 15/288,745). Filed October 17, 2016 and published January 26, 2017. Assignee: Nova Southeastern University 20.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Methods for Use of Epinephrine Fine Particles for Treatment of Conditions Responsive to Epinephrine. US Patent (USPTO) # US 10,159,656 (Appl No 15/288,745). Filled October 17, 2016 and Issued December 25, 2018. Assignee: Nova Southeastern University (Issued Patent). Group 7: Bioavailability and Absorption Studies of Rapidly Disintegrating Sublingual Epinephrine Nanocrystals Tablets (3rd Generation)* 21.Rawas-Qalaji, MM, Rachid, OM, Simons, KJ, Simons, ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Provisional Patent Appl (UPSTO) # 61/804,519. Filed March 22, 2013. Assignee: Nova Southeastern University. Group 6 (NSU13-01): (a) Optimization of Epinephrine Nanocrystals Fabrication (b) Bioavailability and Absorption Studies for 2nd Generation Taste-Masked Rapidly Disintegrating Sublingual Epinephrine Tablets and (c) Sublingual Epinephrine Tablets long-Term Stability Studies 22.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Provisional Patent Appl (UPSTO) # 61/660,273. Filed June 15, 2012. Assignee: Nova Southeastern University 23.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. International Patent Pub (WIPO) # WO/2014/007972 (Appl No PCT/US13/45836). Filed June 14, 2013 and published January 9, 2014. Assignee: Nova Southeastern University 24.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Patent Pub (USPTO) # US2015/0164827 (Appl No 14/408,038). Filed December 15, 2014 and published June 18, 2015. Assignee: Nova Southeastern University 25.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. European Patent Pub (EPO) # EP2861224 (Appl No 13812628). Filed June 14, 2013 and published April 22, 2015. Assignee: Nova Southeastern University 26.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. Canadian Patent Pub (CIPO) # CA2876883 (Appl No 2,876,883). Filed June 14, 2013 and published April 22, 2015. Assignee: Nova Southeastern University 27.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Patent (USPTO) #10,251,849 (Appl No 15/262,961). Filed September 12, 2016 and Issued April 9, 2019. Assignee: Nova Southeastern University (Issued Patent) Group 5 (NSU11-12): (a) Formulation and Characterization of 2nd Generation Taste-Masked Rapidly Disintegrating Sublingual Epinephrine Tablets* and (b) Fabrication of Chitosan Nanoparticles Loaded with Epinephrine 28.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Provisional Patent Application # 61/550,359, Filled October 21, 2011. Assignee: Nova Southeastern University 29.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. International Patent Pub (WIPO) # WO 2013/059629 (Appl No PCT/US12/61074). Filled October 19, 2012 and published April 25, 2013. Assignee: Nova Southeastern University 30.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Patent Pub (USPTO) # US 2014/0242177 (Appl No 14/353,118). Filled April 21, 2014 and published August 28, 2014. Assignee: Nova Southeastern University 31.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. European Patent Pub (EPO) # EP2753321 (Appl No 12842206). Filed April 21, 2014 and published July 16, 2014. Assignee: Nova Southeastern University 32.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. Canadian Patent Pub (CIPO) # CA2853084 (Appl No 2,853,084). Filed April 22, 2014 and published July 16, 2014. Assignee: Nova Southeastern University 33.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Patent Pub (USPTO) # US2017/0000735 (Appl No 15/266,834). Filled September 15, 2016 and published January 05, 2017. Assignee: Nova Southeastern University 34.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Patent (USPTO) # US 9,877,921. Filled September 15, 2016 and Issued January 30, 2018. Assignee: Nova Southeastern University (Issued Patent). 35.Rawas-Qalaji MM, Rachid OM, Simons KJ, Simons ER. Epinephrine Nanoparticles Methods of Fabrication Thereof, and Methods for use Thereof for Treatment of Conditions Responsive to Epinephrine. US Patent Pub (USPTO) # US2018/0147145 (Appl No 15/882,399). Filled January 29, 2018 and published May 31, 2018. Assignee: Nova Southeastern University Group 4 (NSU10-01): Preliminary Epinephrine Nanocrystals Fabrication and Diffusion Studies 36.Rawas-Qalaji MM, Nieves E., Simons KJ, Simons ER, Rachid OM. Composition and Method for Emergency Treatment of Anaphylaxis. US Provisional Patent Appl (UPSTO) # 61/309,136. Filled March 1, 2010. Assignee: Nova Southeastern University 37.Rawas-Qalaji MM, Nieves E., Simons KJ, Simons ER, Rachid OM. Epinephrine Nanoparticles, Methods of Fabrication Thereof, and Methods for Use Thereof for Treatment of Conditions Responsive to Epinephrine. International Patent Application (WIPO) # WO 2011/109340 (Appl No PCT/US11/26604). Filed March 1, 2011 and published September 9, 2011. Assignee: Nova Southeastern University 38.Rawas-Qalaji M.M., Enrique Nieves, Simons K.J., Simons E.R, Rachid O.M. Epinephrine Nanoparticles and Methods of Fabrication Thereof, and Methods for Use Thereof for Treatment of Conditions Responsive to Epinephrine. US Patent Pub (USPTO) # US 2012/0322884 (Appl No 13/582,346). Filed August 31, 2012 and published December 20, 2012. Assignee: Nova Southeastern University 39.Rawas-Qalaji M.M, Simons K.J, Simons E.R, Rachid O.M, Enrique Nieves. Epinephrine Nanoparticles and Methods of Fabrication Thereof, and Methods for Use Thereof for Treatment of Conditions Responsive to Epinephrine. US Patent Pub (USPTO) # US 2017/0071881 (Appl No 15/358,743). Filed November 22, 2016 and published March 16, 2017. Assignee: Nova Southeastern University Group 3: Novel Dissolution Apparatus for Sublingual Tablets 40.Rachid OM, Rawas-Qalaji MM, Simons ER, Simons KJ. Novel Dissolution Apparatus Designed to Evaluate Sublingual Tablets. US Provisional Patent Appl (UPSTO). Filed Nov 1, 2008. Assignee: University of Manitoba Group 2: Bioavailability and Absorption Studies for 1st Generation Rapidly Disintegrating Sublingual Epinephrine Tablets (licensed to Verus Pharma) 41.Rawas-Qalaji MM, Simons KJ, Gu X, Simons ER. Fast-Disintegrating Epinephrine Tablets for Buccal or Sublingual Administration. US Provisional Patent Appl (UPSTO) # 60/759,039. Filed Jan. 17, 2006. Assignee: University of Manitoba. (Assignment released to NSU). 42.Rawas-Qalaji MM, Simons KJ, Gu X, Simons ER. Fast-Disintegrating Epinephrine Tablets for Buccal or Sublingual Administration. US Patent Pub (USPTO) # US 2007/0202163 (Appl No 11672503). Filed Feb. 7, 2007 and published August 30, 2007. Assignee: University of Manitoba (Assignment released to NSU). 43.Rawas-Qalaji MM, Simons KJ, Gu X, Simons ER. Fast-Disintegrating Epinephrine Tablets for Buccal or Sublingual Administration. International Patent Pub (WIPO) # WO 2008/095284 (Appl No PCT/CA2008/000197), Filed Jan. 31, 2008 and published August 14, 2008. Assignee: University of Manitoba (Assignment released to NSU). Group 1: Formulation and Characterization of 1st Generation Rapidly Disintegrating Sublingual Epinephrine Tablets (licensed to Verus Pharma) 44.Rawas-Qalaji MM, Simons KJ, Gu X, Simons ER. Fast-Disintegrating Epinephrine Tablets for Buccal or Sublingual Administration. US Provisional Patent Appl (UPSTO) # 60/715,180. Filed Sep. 9, 2005. Assignee: University of Manitoba (Assignment released to NSU). 45.Rawas-Qalaji MM, Simons KJ, Gu X, Simons ER. Fast-Disintegrating Epinephrine Tablets for Buccal or Sublingual Administration. US Patent Pub (USPTO) # US 2007/0059361 (Appl No 11530360). Filed Sep. 8, 2006 and published March 15, 2007. Assignee: University of Manitoba (Assignment released to NSU). 46.Rawas-Qalaji MM, Simons KJ, Gu X, Simons ER. Fast-Disintegrating Epinephrine Tablets for Buccal or Sublingual Administration. International Patent Pub (WIPO) # WO 2007/028247 (Appl No PCT/CA2006/001472). Filed Sep. 8, 2006 and published March 15, 2007. Assignee: University of Manitoba (Assignment released to NSU).
Research Recognitions 1)Recognized as Outstanding Faculty by Provost Ralph V. Rogers at the NSU Board of Trustees Meeting (April 17, 2017). 2)Featured on various US News channels including WPLG-Local10 TV (FL), KFSN-ABC 30 TV (CA), Waay-31 abc TV (AL), WKBT-News 8 TV (WI), Click2Houston TV (TX), WJRT-ABC12 TV (MI), KFDX 3 TV (TX), WTJA TV (PA), WFMZ-69 News TV (PA, NJ), Ivanhoe Broadcast News, and Ivanhoe Broadcast. 3)Featured in CNBC, Life Sciences South Florida, Popular Sciences, Digital Trends, Snack Safely, Trend Hunter Tech, Biospace, Extreme Tech, Trigger Allergy, WeAreGreenBay, ZME Science, and NSU Realizing Potential Newsletter 4)Featured in YouTube https://youtu.be/p37ZnjOMh3o, https://youtu.be/Gsj15oNaXcg. 5)Selected as a Faculty Speaker and recognized during the Celebration of Excellence, Nova Southeastern University (Jan 28, 2017). 6)Invited as a speaker during the NSU Ambassadors Board, Nova Southeastern University (Feb 9, 2017) 7)Poster was selected for the best poster award (3rd place) during the 126th Florida Pharmacy Association Annual Meeting and Convention, Fort Lauderdale, FL (June 30-July 3, 2016) 8)Recognized as Outstanding Faculty by Provost Ralph V. Rogers at the NSU Board of Trustees Meeting (Nov 16, 2015). 9)Pre-IND filling and meeting with FDA was recognized during the Department Meeting by College of Pharmacy Dean, Associate Dean for Research, and Department Chair (Oct 14, 2015). 10)External funding was recognized by President George Hanbury during the 2014 External Funding Recognition Reception, Nova Southeastern University (2014, 2016) 11)Poster was selected for the best poster award (1st place) during the Manitoba Society of Pharmacists Annual Conference, Winnipeg, Manitoba, Canada (April 25-27, 2014) 12)Abstract was selected for a featured poster presentation as the “Best of Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA)” by the Review Committee of the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Program, San Diego, CA (Feb 28- Mar 4, 2014) 13)Recognized by President George Hanbury, President of Nova Southeastern University, during the Annual Faculty Reception (October 2013). 14)Research project and inventions were featured in Research and Technology Transfer Office Annual Report, Nova Southeastern University (2011 – present) 15)Research and mentorship activities were featured in Florida Pharmacy Today, 2013, 76 May (5): 17. Official publication of the Florida Pharmacy Association 16)Selected for Grant Writing Workshop sponsored by National Institute of General Medical Sciences (NIMGS) at National Institutes of Health (NIH), University of Kentucky (2012). 17)Selected for the front page of the Research and Technology Transfer Office Annual Report, Nova Southeastern University (2011) 18)Featured in Florida Trend magazine’s research issue (2011). Teaching Awards 19)Nominated for Student Life Achievement Award at the university level by the College of Pharmacy Awards Committee, Nova Southeastern University (2014). 20)Selected the Professor of the Year, College of Pharmacy Awards Committee, Nova Southeastern University (2014). 21)Nominated for the Golden Apple Award, College of Pharmacy, Nova Southeastern University to be recognized at the American Association of Colleges of Pharmacy (2010). 22)The Best Teacher Award for the 1st year pharmacy students, College of Pharmacy, Nova Southeastern University (2010). Postdoctoral Fellowship Award 23)Natural Sciences and Engineering Research Council (NSERC) Industrial Postdoctoral Fellowship (2007) ($40,000/year for 2 years). Ph.D. Graduate Awards 2006 24)Manitoba Health Research Council (MHRC) Award ($16,000.00 CAD). 25)The Canadian Foundation for Pharmacy (CFP) National Best Poster Award. 26)Strategic Training in Allergy Research (ST*AR) Award - American Academy of Allergy, Asthma & Immunology’s (AAAAI) ST*AR Program – March 3-7, 2006, Miami Beach, FL. 27)AAPS-UManitoba Pharmacy Student Chapter Research Abstract Competition Award ($100.00 CAD). 28)Manitoba Institute of Child Health (MICH) Travel Award ($1,400.00 CAD) 29)University of Manitoba Graduate Students Association (UMGSA) Conference Travel Grant ($200.00 CAD). 30)University of Manitoba Student Union (UMSU) Travel Award ($200.00 CAD). 31)The Alumni Association Inc. of The University of Manitoba Conference Travel Grant ($140.00 CAD). 2005 32)Manitoba Health Research Council (MHRC) Studentship Award ($16,000.00 CAD). 33)Manitoba Institute of Child Health (MICH) Travel Award ($1,400.00 CAD). 34)University of Manitoba Graduate Student Conference Travel Award ($500.00 CAD). 35)University of Manitoba Student Union (UMSU) Travel Award ($200.00 CAD). 36)University of Manitoba Graduate Students Association (UMGSA) Conference Travel Grant ($200.00 CAD). 37)The Alumni Association Inc. of The University of Manitoba Conference Travel Grant ($140.00 CAD). 2004 38)Honourable Mention-The Manitoba Health Research Council (MHRC) Poster Competition, Faculty of Medicine, University of Manitoba. 39)University of Manitoba Graduate Fellowship (UMGF) Award ($14,000.00 CAD). 40)Manitoba Pharmaceutical Association (MPhA) Graduate Scholarship ($2,000.00 CAD). 41)University of Manitoba Student Union (UMSU) Scholarship Award ($200.00 CAD). 42)Manitoba Institute of Child Health (MICH) Travel Award ($1,400.00 CAD). 43)University of Manitoba Graduate Student Conference Travel Award ($200.00 CAD). 44)University of Manitoba Student Union (UMSU) Travel Award ($200.00 CAD). 45)University of Manitoba Bursary ($2000.00 CAD). 2003 46)Manitoba Institute of Child Health (MICH) Graduate Award ($16,000.00 CAD). 47)University of Manitoba Bursary ($2000.00 CAD). 2002 48)University of Manitoba Graduate Fellowship (UMGF) Award ($14,000.00 CAD). 49)University of Manitoba Bursary ($2000.00 CAD). 2001 50)Manitoba Institute of Child Health (MICH) Graduate Award ($16,000.00 CAD). F. Hoffmann La-Roche Awards (1996-2000) 51)The Pharma International Award of Excellence, Basel, Switzerland (1997). 52)Winner - Territory Management Simulation, Riyadh, Saudi Arabia (1997). 53)Product Champion in marketing Glucagon® (2000), Rocephin® (2000), Tilcotil® (1999), Coreg® (1999), and Bactrim® (1996), Riyadh, Saudi Arabia. 54)Product Runner-Up in marketing Rocephin® (1999), Manerix® (1996), and Dormicum® (1996), Riyadh, Saudi Arabia. Pharmacy Graduate Awards (1994-1995) 55)Academic Excellence Award, King Saud University, Riyadh, Saudi Arabia (1994-1995). 56)Student Fund Award, King Saud University, Riyadh, Saudi Arabia (1995) ($1000.00 SAR). 57)Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO) Training Award, Saudi Arabia (1995) ($2000.00 SAR).
 Founding Director for the Center for Drug Discovery and Development (CD3), NSU (2016-present)  Advisory Board Member, SanMelix Laboratories, Pembroke Pines, Florida, USA (2018)  Executive Committee Member, Arab American Pharmaceutical Scientists, USA (2018-present)  Board Member, South Florida Chapter, Syrian American Medical Society (SAMS), USA (2015-present)  Board Member, Florida Refugee Assist Committee, Florida, USA (2015-2019)  Board Member, STEM School, Sunrise, Florida, USA (2018-2019)
My teaching philosophy relies on “Quality not Quantity of Information” philosophy. I focus on the most important aspects of the topic I teach; facilitate student learning through course planning and organization; and utilize a variety of teaching strategies and active learning activities to deliver course content and motivate students. In the end, what really matters in my opinion, is the level of student understanding and the comprehensiveness of this understanding, and not how many handouts they have to study for the exam. I believe that Pharmaceutics is a critical field that provides pharmacists with the knowledge of drug delivery and dosage forms. It is essential to making the role of the pharmacist unique among those of other health care professionals.
Back to list